As Herceptin biosimilars eat into Roche sales, Swiss drugmaker makes case for expanded Kadcyla use
As the biosimilar sharks bite into the sales of Roche’s decades-old blockbuster Herceptin, the Swiss drugmaker is betting on the broader use of Kadcyla, an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
